When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions BPC 157 and the Difference Between an Evidence Gap and a Cover Up: What the entire human evidence base actually looks like, and the questions to ask next. WellFounded Founders Health & FDA Decisions Expected: October 2025 Prime Therapeutics Portal The Peptide Craze Part 2: BPC 157, NAD and the Truth Behind the Longevity Molecule Hype FDA mulls compounding for peptides previously flagged over safety risks BioSpace A new FDA advisory panel meeting, influenced by RFK Jr.'s push for broader access, will weigh the potential benefits and risks of widely promoted peptides. Click the link in bio to read